# Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer

> **NCT03513211** · PHASE1,PHASE2 · COMPLETED · sponsor: **St Vincent's Hospital, Sydney** · enrollment: 12 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** SUBA-itraconazole
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT03513211
- **Lead sponsor:** St Vincent's Hospital, Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03513211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03513211, "Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03513211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*